Cargando…
Caenorhabditis elegans provides an efficient drug screening platform for GNAO1-related disorders and highlights the potential role of caffeine in controlling dyskinesia
Dominant GNAO1 mutations cause an emerging group of childhood-onset neurological disorders characterized by developmental delay, intellectual disability, movement disorders, drug-resistant seizures and neurological deterioration. GNAO1 encodes the α-subunit of an inhibitory GTP/GDP-binding protein r...
Autores principales: | Di Rocco, Martina, Galosi, Serena, Lanza, Enrico, Tosato, Federica, Caprini, Davide, Folli, Viola, Friedman, Jennifer, Bocchinfuso, Gianfranco, Martire, Alberto, Di Schiavi, Elia, Leuzzi, Vincenzo, Martinelli, Simone |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947233/ https://www.ncbi.nlm.nih.gov/pubmed/34622282 http://dx.doi.org/10.1093/hmg/ddab296 |
Ejemplares similares
-
Phenotypic Assessment of Pathogenic Variants in GNAO1 and Response to Caffeine in C. elegans Models of the Disease
por: Di Rocco, Martina, et al.
Publicado: (2023) -
The recurrent pathogenic Pro890Leu substitution in CLTC causes a generalized defect in synaptic transmission in Caenorhabditis elegans
por: Pannone, Luca, et al.
Publicado: (2023) -
Highlighting the Dystonic Phenotype Related to
GNAO1
por: Wirth, Thomas, et al.
Publicado: (2022) -
GNAO1 encephalopathy: Broadening the phenotype and evaluating treatment and outcome
por: Danti, Federica Rachele, et al.
Publicado: (2017) -
CLINICAL TRIAL HIGHLIGHTS – DYSKINESIA
por: McFarthing, Kevin, et al.
Publicado: (2019)